Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.66 USD | -2.76% | +2.96% | +28.84% |
May. 13 | Piper Sandler Adjusts Price Target on Myriad Genetics to $28 From $23, Maintains Neutral Rating | MT |
May. 08 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.84% | 2.23B | |
-4.62% | 12.32B | |
+8.48% | 5.87B | |
+28.39% | 5.52B | |
-6.28% | 4.29B | |
-52.84% | 3.16B | |
+12.93% | 2.72B | |
-3.80% | 2.37B | |
-4.64% | 1.87B | |
+2.20% | 1.59B |
- Stock Market
- Equities
- MYGN Stock
- News Myriad Genetics, Inc.
- (MYGN) MYRIAD GENETICS Forecasts Fiscal Year 2023 Revenue Range $747M - $753M